Krzysztof Brzozka

Company: Ryvu Therapeutics

Job title: Chief Scientific Officer

Seminars:

Developing a Comprehensive Platform for Identification of Synthetic Lethal Targets Using Patient-Derived Cells 12:30 pm

Combining the scalability of high-throughput technologies with the unmatched precision and translational relevance of advanced primary models in Ryvu’s cutting-edge drug discovery platform Leveraging human stem cell-derived models, patient-derived xenografts (PDXs), and clinical samples to establish a groundbreaking approach in uncovering synthetic lethal (SL) targets uniquely tied to oncogenic pathways Using our proprietary ranking algorithm…Read more

day: Conference Day Two